Esreboxetine

Esreboxetine (developmental code names AXS-14, PNU-165442G) is a selective norepinephrine reuptake inhibitor which was under development by Pfizer for the treatment of neuropathic pain and fibromyalgia but failed to show significant benefit over currently available medications and was discontinued.^[1][2][3][4] It is the (S,S)-(+)-enantiomer of reboxetine and is even more selective as a norepinephrine reuptake inhibitor in comparison.^[1][5]

Other namesAXS-14; PNU-165442G

Routes of
administrationOral

ATC code

• None

Legal status

• In general: uncontrolled

Quick facts Clinical data, Other names ...

Esreboxetine

Clinical data
Other names	AXS-14; PNU-165442G
Routes of administration	Oral
ATC code	None
Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name (2S)-2-[(S)-(2-ethoxyphenoxy)phenyl methyl]morpholine
CAS Number	98819-76-2 Y
PubChem CID	65856
IUPHAR/BPS	4808
ChemSpider	59268 N
UNII	L8S50ZY490
KEGG	D09340 Y
CompTox Dashboard (EPA)	DTXSID601009938
Chemical and physical data
Formula	C19H23NO3
Molar mass	313.397 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3
InChI InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m0/s1 N Key:CBQGYUDMJHNJBX-OALUTQOASA-N N
NY (what is this?)  (verify)

Close

However, recently it has been found that esreboxetine could be effective in fibromyalgia patients.^[6]